Liposomes as tunable platform to decipher the antitumor immune response triggered by TLR and NLR agonists.

TLR4 liposome containing MPLA (adjuvant), Th (HA) and tumor specific (E7) peptides is a very potent cancer vaccine capable of inducing a strong cytotoxic immune response against tumor cells. The subcutaneous administration of the vaccine (1) induce the migration of CD103− dermal DC into the draining lymph nodes (2–3) followed by the differentiation of Th and CTL lymphocytes (4) leading to the specific recognition and destruction of tumor cells (5–6).